Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Page 1
Patterns of atrial fibrillation anticoagulation with rivaroxaban - 7-year follow-up from the Dresden NOAC registry.
Tittl L, Marten S, Naue C, Beyer-Westendorf J. Tittl L, et al. Among authors: beyer westendorf j. Thromb Res. 2024 Apr;236:61-67. doi: 10.1016/j.thromres.2024.02.014. Epub 2024 Feb 19. Thromb Res. 2024. PMID: 38394987 Free article.
INTRODUCTION: Data on long-term effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) are scarce and not available from randomized clinical trials. ...Of note, rates of fatal bleeding were low throughout follow-up (0.2 vs. 0.2 vs. 0.1/ …
INTRODUCTION: Data on long-term effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) are scarc …
Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study.
Rabe E, Hoffmann U, Schimke A, Heinken A, Langer F, Noppeney T, Pittrow D, Klotsche J, Gerlach HE, Bauersachs R; INSIGHTS-SVT Study Collaborators. Rabe E, et al. Eur J Vasc Endovasc Surg. 2023 Nov;66(5):697-704. doi: 10.1016/j.ejvs.2023.08.031. Epub 2023 Aug 12. Eur J Vasc Endovasc Surg. 2023. PMID: 37573936 Free article.
OBJECTIVE: Long term incidence of symptomatic venous thromboembolism (VTE) and bleeding events in patients with superficial vein thrombosis (SVT) was investigated. ...
OBJECTIVE: Long term incidence of symptomatic venous thromboembolism (VTE) and bleeding events in patients with superficial vein thro …
Direct Oral Anticoagulants: Laboratory Challenges and Antidotes.
Beyer-Westendorf J, Köhler C. Beyer-Westendorf J, et al. Hamostaseologie. 2023 Feb;43(1):37-43. doi: 10.1055/a-1987-3559. Epub 2023 Feb 20. Hamostaseologie. 2023. PMID: 36807818 Free article.
Challenges for the emergency physician result from the increasing age of DOAC anticoagulated patients, the difficulties to establish last intake of DOAC type and dosage, to interpret coagulation test results in emergency situations, and to make decisions for or against DOAC rever …
Challenges for the emergency physician result from the increasing age of DOAC anticoagulated patients, the difficulties to establish last in …
Predictive ability of viscoelastic testing using ClotPro for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study.
Heubner L, Greiner M, Vicent O, Beyer-Westendorf J, Tiebel O, Scholz U, Güldner A, Mirus M, Fries D, Koch T, Spieth PM. Heubner L, et al. Among authors: beyer westendorf j. Thromb J. 2022 Aug 29;20(1):48. doi: 10.1186/s12959-022-00403-0. Thromb J. 2022. PMID: 36038895 Free PMC article.
Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin.
Bistervels IM, Bavalia R, Beyer-Westendorf J, Ten Cate-Hoek AJ, Schellong SM, Kovacs MJ, Falvo N, Meijer K, Stephan D, Boersma WG, Ten Wolde M, Couturaud F, Verhamme P, Brisot D, Kahn SR, Ghanima W, Montaclair K, Hugman A, Carroll P, Pernod G, Sanchez O, Ferrari E, Roy PM, Sevestre-Pietri MA, Birocchi S, Wik HS, Hutten BA, Coppens M, Naue C, Grosso MA, Shi M, Lin Y, Quéré I, Middeldorp S; Hokusai PTS Investigators. Bistervels IM, et al. Among authors: beyer westendorf j. Res Pract Thromb Haemost. 2022 Jul 1;6(5):e12748. doi: 10.1002/rth2.12748. eCollection 2022 Jul. Res Pract Thromb Haemost. 2022. PMID: 35992565 Free PMC article.
BACKGROUND: Postthrombotic syndrome (PTS) is a long-term complication after deep vein thrombosis (DVT) and can affect quality of life (QoL). ...OBJECTIVES: To compare the prevalence of PTS after acute DVT and the long-term QoL following DVT between patients treated …
BACKGROUND: Postthrombotic syndrome (PTS) is a long-term complication after deep vein thrombosis (DVT) and can affect quality of life …
Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry.
Pfeilschifter W, Lindhoff-Last E, Alhashim A, Zydek B, Lindau S, Konstantinides S, Grottke O, Nowak-Göttl U, von Heymann C, Birschmann I, Beyer-Westendorf J, Meybohm P, Greinacher A, Herrmann E; RADOA-Registry Investigators (Reversal Agent use in patients treated with Direct Oral Anticoagulants or vitamin K antagonists Registry). Pfeilschifter W, et al. Among authors: beyer westendorf j. Neurol Res Pract. 2022 May 2;4(1):16. doi: 10.1186/s42466-022-00183-y. Neurol Res Pract. 2022. PMID: 35491419 Free PMC article.
The primary endpoint was in-hospital mortality until day 30. We evaluated hematoma volume and short-term clinical outcomes in relation to the extent of active OAT according to coagulation parameters and OAT plasma levels measured by UPLC-MS/MS. ...
The primary endpoint was in-hospital mortality until day 30. We evaluated hematoma volume and short-term clinical outcomes in relatio …
Long-term VTE treatment with rivaroxaban: Results from the DRESDEN NOAC REGISTRY.
Marten S, Naue C, Tittl L, Bornhauser M, Beyer-Westendorf J. Marten S, et al. Among authors: beyer westendorf j. Thromb Res. 2021 Dec;208:181-189. doi: 10.1016/j.thromres.2021.11.006. Epub 2021 Nov 16. Thromb Res. 2021. PMID: 34808410
Data on long-term effectiveness and safety of venous thromboembolism (VTE) treatment with rivaroxaban are scarce and not available from randomized clinical trials. ...Our results confirm low thrombotic and major bleeding rates for long-term VTE treatment with rivaro …
Data on long-term effectiveness and safety of venous thromboembolism (VTE) treatment with rivaroxaban are scarce and not available fr …
Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin.
Bavalia R, Bistervels IM, Boersma WG, Quere I, Brisot D, Falvo N, Stephan D, Couturaud F, Schellong S, Beyer-Westendorf J, Montaclair K, Ghanima W, Ten Wolde M, Coppens M, Ferrari E, Sanchez O, Carroll P, Roy PM, Kahn SR, Meijer K, Birocchi S, Kovacs MJ, Hugman A, Ten Cate H, Wik H, Pernod G, Sevestre-Pietri MA, Grosso MA, Shi M, Lin Y, Hutten BA, Verhamme P, Middeldorp S; Hokusai post‐PE study investigators. Bavalia R, et al. Among authors: beyer westendorf j. Res Pract Thromb Haemost. 2021 Jul 14;5(5):e12566. doi: 10.1002/rth2.12566. eCollection 2021 Jul. Res Pract Thromb Haemost. 2021. PMID: 34278193 Free PMC article.
BACKGROUND: Long-term sequelae of acute pulmonary embolism (PE) include decreased quality of life (QoL). ...CONCLUSION: Our findings indicate that patients with an index PE treated with edoxaban or warfarin have a similar long-term QoL. Since our study was a follow- …
BACKGROUND: Long-term sequelae of acute pulmonary embolism (PE) include decreased quality of life (QoL). ...CONCLUSION: Our findings …
5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry.
Tittl L, Marten S, Naue C, Beyer-Westendorf J. Tittl L, et al. Among authors: beyer westendorf j. Thromb Res. 2021 Jun;202:24-30. doi: 10.1016/j.thromres.2021.03.004. Epub 2021 Mar 8. Thromb Res. 2021. PMID: 33711755
Rivaroxaban treatment discontinuation occurred in a total of 574 patients during follow-up (11.0/100 patient-years in Kaplan-Meier analysis) and 426 patient died (all-cause mortality 6.3/100 pt. years; mean time from enrolment 3.6 2.1 years), of which the causes of death were rep …
Rivaroxaban treatment discontinuation occurred in a total of 574 patients during follow-up (11.0/100 patient-years in Kaplan-Meier analysis) …
39 results